Antiretrovirals and the kidney in current clinical practice: Renal pharmacokinetics, alterations of renal function and renal toxicity

AIDS

Volumn 28, Issue 5, 2014, Pages 621-632

  Yombi, Jean C ^a,b   Pozniak, Anton ^b   Boffito, Marta ^b   Jones, Rachael ^b   Khoo, Saye ^c   Levy, Jeremy ^d   Post, Frank A ^e  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Estimated glomerular filtration rate; HIV; Kidney; Pharmacokinetics; Therapy; Transporters

Indexed keywords

ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CIDOFOVIR; COBICISTAT PLUS ATAZANAVIR; COBICISTAT PLUS DARUNAVIR; COBICISTAT PLUS ELVITEGRAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; DARUNAVIR PLUS RITONAVIR; DAUNORUBICIN; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; FUROSEMIDE; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROBENECID; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIRETROVIRUS AGENT;

ACUTE KIDNEY FAILURE; APICAL MEMBRANE; BASOLATERAL MEMBRANE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DRUG HALF LIFE; ELECTRON MICROSCOPY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE CELL; KIDNEY TUBULE DISORDER; NEPHRITIS; NEPHROLITHIASIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMICALLY INDUCED; DRUG EFFECTS; HIV INFECTIONS; KIDNEY; KIDNEY FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY;

AIDS-ASSOCIATED NEPHROPATHY; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS;

EID: 84898759641     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000103     Document Type: Review

References (113)

1. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24: 1527-1535.
2. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIVinfected persons compared with the general population. Clin Infect Dis 2011; 53: 1120-1126.
3. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-1139.
4. Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis 2009; 22: 43-48.
5. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121: 651-658.
6. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24: 387-394.
7. Campbell LJ, Desai M, Hegazi A, Ibrahim F, Melikian N, Hay P, et al. Renal impairment is associated with coronary heart disease in HIV-positive men. HIV Clin Trials 2012; 13: 343-349.
8. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis 2012; 60: 539-547.
9. Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, et al. Clinical epidemiology of HIV-associated end-stage renal failure in the UK. AIDS 2009; 23: 2517-2521.
10. Ryom L, Kirk O, Lundgren J, Reiss P, Pedersen C, De Wit S, et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013; 14: 503-508.
11. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678.
12. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D: A: D study. J Infect Dis 2013; 207: 1359-1369.
13. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-875.
14. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46: 1271-1281.
15. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481-487.
16. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 2009; 54: 1034-1042.
17. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009; 10: 329-336.
18. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
19. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10: 482-487.
20. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25: 1671-1673.
21. Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, et al. High incidence of renal stones among HIVinfected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-1269.
22. Zolopa A, Sax PE, Dejesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63: 96-100.
23. Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, et al. A randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62: 483-486.
24. Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, Mehsen N, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011; 80: 302-309.
25. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290.
26. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, noninferiority trial. Lancet 2012; 379: 2429-2438.
27. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. The effects of HIV type-1 viral suppression and nonviral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 2009; 14: 543-549.
28. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78: 1171-1177.
29. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21: 1215-1218.
30. Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007; 450: 665-670.
31. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
32. Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 2013; 14: 49-59.
33. de Lastours V, Ferrari Rafael De Silva E, Daudon M, Porcher R, Loze B, Sauvageon H, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 2013; 68: 1850-1856.
34. Curtis LD, Min S, Nichols G, Wynne B, Stainsby C, Aylott A, et al. Once-daily dolutegravir (DTG; nGSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-naive adults: 48 week results from SPRING-2 (ING113086) abd SINGLE (ING114467). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 June-3 July 3 2013; Kuala Lumpur, Malaysia.
35. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012; 60: 33-42.
36. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 2013; 208: 32-39.
37. Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scand J Infect Dis 2013; 45: 147-154.
38. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray AS. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2011. Chicago. Abstract A1-1724.
39. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
40. Muller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011; 12: 1017-1037.
41. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-665.
42. Ward PD, La D, McDuffie JE. In: Gowder S, editor. Renal transporters and biomarkers in safety assessment, new insights into toxicity and drug testing. InTech; 2013. ISBN: 978-953-51-0946-4, doi: 10.5772/54857. http://www. intechopen.com/books/new-insights-into-toxicity-and-drug-testing/ renal-transporters-and-biomarkers-in-safety-assessment.
43. Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. J Acquir Immune Defic Syndr 2013; 62: 275-281.
44. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47: 298-303.
45. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009; 10: 1675-1685.
46. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-153.
47. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48: e108-e116.
48. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-1491.
49. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy. HIV Med 2006; 7: 105-111.
50. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198.
51. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49-57.
52. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-2448.
53. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-246.
54. Vrouenraets SM, Fux CA, Wit FW, Garcia EF, Furrer H, Brinkman K, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 2011; 25: 2149-2155.
55. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007; 12: 1165-1173.
56. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108.
57. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83: 265-272.
58. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61: 32-40.
59. Mathias A, Lee M, Callebaut C, Xu L, Tsai L, Murray B, et al. GS-9350: a pharmaco-enhancer without anti-HIV activity. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal. Abstract 40.
60. Sax PE, Tierney C, Collier A C, Daar E S, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-1201.
61. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant 2011; 26: 3224-3229.
62. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269-273.
63. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341-346.
64. Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis 2012; 44: 689-696.
65. de Silva TI, Post FA, Griffin MD, Dockrell DH. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin Proc 2007; 82: 1103-1116.
66. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS 2010; 24: 2239-2244.
67. Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 2010; 78: 1060-1063.
68. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304.
69. Jose S, Hamzah L, Campbell L, Nitsch D, Jones R, Sabin C, et al. Reversibility of tenofovir-associated decline in renal function. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
70. Cihlar T, Laflamme G, Fisher R, Carey AC, Vela JE, Mackman R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother 2009; 53: 150-156.
71. Zolopa A Ortiz R, Sax P, Brar I, Elion R, Wang H, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
72. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-291.
73. Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12: 267-272.
74. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
75. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009; 69: 1107-1140.
76. Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials 2012; 13: 189-211.
77. Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med 2011; 12: 620-631.
78. Albini L, Cesana BM, Motta D, Foca E, Gotti D, Calabresi A, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 2012; 59: 18-30.
79. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-332.
80. Young J, Schafer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26: 567-575.
81. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44: e81-e84.
82. Elens L, Tyteca D, Panin N, Courtoy P, Lison D, Demoulin JB, et al. Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics 2011; 21: 884-893.
83. Holodniy M. Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy. Drugs 2007; 67: 2803.
84. Boffito M, Jackson A, Amara A, Back D, Khoo S, Higgs C, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 h following drug cessation. Antimicrob Agents Chemother 2011; 55: 4218-4223.
85. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-1059.
86. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 2009; 87: 1023-1036.
87. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52: 1663-1669.
88. Mathias AA, German P, Murray BP, Wei L, Jain A, West S, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87: 322-329.
89. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7: 390-400.
90. Ramanathan S, Custodio J, Wang H, Dave A, Cheng A, Kearney BP. Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla) in healthy subjects. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain.
91. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50: 229-244.
92. Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al. Phase 2 study of cobicistat versus ritonavir each with oncedaily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011; 25: 1881-1886.
93. Ramanathan WD, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 11-15 September 2009; San Francisco, CA.
94. Ramanathan WH, Szwarcberg J, Kearney BP. Safety/tolerability, pharmacokinetics, and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain.
95. Mathias LH, Warren D, Sekar V, Kearney BP. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 5-7 April 2010; Sorrento, Italy.
96. Ramanathan RM, Shen G, Custodio J, Kearney BP. Pharmacokinetics and safety of boosted-elvitegravir in subjects with hepatic impairment. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain.
97. Benson C, Mayer C, Morales Ramirez J, Winston J, Rhee MS, Szwarcberg J. Renal safety profile of Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and of cobicistat-boosted atazanavir plus emtricitabine/tenofovirTFV DF in HIV patients.Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 11-15 September 2012; San Francisco, CA.
98. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics (PK) and safety in healthy subjects of S/GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
99. Soriano V, Cox J, Eron J, Kumar P, Katlama C, Lazzarin A, et al. Dolutegravir (DTG, S/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 in the Viking Study. 13th European AIDS Conference; 12-15 October 2011; Belgrade, Serbia.
100. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013; 41: 353-361.
101. Song I, Borland J, Chen S, Peppercorn A, Savina P, Wajima T, et al. Metabolism and drug-drug interaction profile of dolutegravir (DTG, S/GSK1349572). 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain.
102. Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75: 990-996.
103. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381: 735-743.
104. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 51: 1376-1402.
105. Masia M, Enriquez R, Sirvent A, Gutierrez F. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 2010; 61: 189-190.
106. Moss D, Siccardi M, Khoo S, Back D, Owen A, et al. The interactions between rilpivirine and drug transporters in vitro. 19th Conference of Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, WA.
107. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial. Lancet 2011; 378: 229-237.
108. Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomised trials. AIDS 2013; 27: 939-950.
109. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13: 1-44.
110. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585.
111. EACS. Prevention and management of noninfectious co-morbidities in HIV. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf [Accessed 1 September 2013].
112. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS 2010; 5: 524-530.
113. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2): 1-85.